Carregant...
Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries
PURPOSE: Novel parenteral (bortezomib) and oral (lenalidomide) therapies have improved survival in myeloma, but the standard Medicare benefit covers only parenteral drugs. We examined the association between prescription drug coverage, receipt of therapy, and survival among Medicare beneficiaries wi...
Guardat en:
| Publicat a: | J Clin Oncol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Clinical Oncology
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6366642/ https://ncbi.nlm.nih.gov/pubmed/30113885 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2018.77.8894 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|